Laura Board is The Deal’s international editor. Based in London, she leads a team producing news and features on corporate finance and regulation from Brussels to Brisbane. Board joined the The Deal shortly after its 1999 launch from the Financial Times. Before that, she worked at Bloomberg News in Frankfurt and London and at Retail Week. She speaks French, Italian, German and Spanish.
A new Harry Potter-themed attraction pushes theme park sales up 61%.
But the U.K. lender stands by its financial targets and reports better-than-expected capital generation in the third quarter.
Shareholders will also strain for information on the post-Brexit outlook at the Edinburgh lender.
The group's Keytruda immunotherapy boosts pharmaceuticals sales.
The stronger-than-expected data, following robust German purchasing managers' indices on Monday, fuel optimism about the fourth-quarter outlook..
The chip maker sinks on news of production problems and a gloomy fourth-quarter prognosis.
The group's blood cancer drug Gleevec also holds up better than expected against generic competition.
The Swiss fertilizers maker says regulators in the EU and elsewhere have demanded more information.
The complex transaction will add a fifth to TD Ameritrade's client assets.
Markit says the data, which follow disappointing September numbers, are consistent with 0.4% quarterly GDP growth.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.